GLP-1 Telehealth Affiliate Programs: Evaluation Checklist
GLP-1 Telehealth Affiliate Programs: Evaluation Checklist

Evaluate a GLP-1 telehealth program by confirming the actual clinical service, the provider's licensed states, how eligibility and treatment are described, and the affiliate terms and creative you'd use. Promote only licensed clinical programs. Never promote "research use only" GLP-1 products, and never imply a compounded drug is the same as a brand-name medicine.
GLP-1 programs are some of the most searched telehealth offers, and some of the most closely watched by regulators. This checklist helps you separate well-run programs from risky ones.
Identify the actual clinical service
Write down exactly what the patient receives:
- A clinical membership (clinician visits, follow-ups, labs).
- Medication: branded, compounded where the prescriber and pharmacy determine it's permitted, or billed separately.
- Support: nutrition, coaching, side-effect questions.
If a site sells GLP-1 products without a clinician's evaluation, or labels them "research use only," it's not a telehealth program. FDA has issued warning letters to sellers using "research use only" labels while marketing GLP-1s for human use.
Verify provider scope and markets
- The provider company and clinical group are named.
- Clinicians are licensed in the states where the program enrolls patients; ask for the list.
- The dispensing pharmacy is identified.
- For paid ads, the provider holds LegitScript certification (required by Google for US telemedicine advertising).
Review eligibility and treatment descriptions
- Eligibility is described as a clinician's decision, not a self-qualification promise.
- Treatment descriptions avoid outcome promises such as specific weight loss.
- Compounded programs are described as compounded. On March 3, 2026, FDA sent 30 warning letters to telehealth companies over compounded GLP-1 marketing that implied sameness with FDA-approved drugs or hid who compounded the product (FDA).
- Pricing shows what's included and what renews.
Check affiliate terms and creative
- Payable event: completed intake, first paid month or first fill.
- Reversals: refunds, cancellations, chargebacks, and the window.
- Recurring credit, if any.
- Traffic rules: paid search and social are usually approval-only.
- Approved claims, images and landing pages, plus disclosure requirements.
Rules still moving: FDA proposed on April 30, 2026, to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list; a final decision is pending. Check the telehealth regulation tracker for the latest, and the ad platform rules before running paid traffic.
Complete the program checklist
- It's a licensed clinical service, not a product sold without evaluation
- Provider, clinical group and pharmacy are named
- Licensed states are listed
- Eligibility is framed as a clinician's decision
- No weight-loss amounts or timelines in approved creative
- No "same as" or "generic" claims for compounded medication
- No "GLP-1 + B12" or other blends promoted as different from the approved drug (FDA warning letter, September 2026)
- Pricing, renewals and cancellation are clear
- Payable event and reversals are in writing
- Traffic rules and disclosure requirements are understood
Frequently asked questions
Who is this guide for?
Publishers considering GLP-1 telehealth offers, from weight management sites to health newsletters.
What should I gather before I start?
The provider's details, licensed states, pharmacy, pricing page, approved claims and the program's payout and traffic terms.
How should I judge the result?
A program that passes every item, retains patients and has clear terms is worth promoting. If any item fails, ask the advertiser before sending traffic.
Practical guides and programs for health and beauty publishers.
Educational content for marketers and publishers, not medical, legal or financial advice. Examples labeled hypothetical are illustrations, not results. MarketHealth may earn revenue from programs it describes. See our affiliate disclosure and editorial policy.


